Payment overview · 2025
General Payments
$45.38
2 reported records · 2 companies
Healthcare provider profile · identity verified
Raymond Joseph Howard, MD
Allopathic & Osteopathic Physicians|Family Medicine · BELFAST, ME · NPI 1295199719
Verified facts
What the public records show
CMS Open Payments records show Raymond Joseph Howard, MD received $45.38 in general payments during 2025 across 2 reported records.
SUN PHARMACEUTICAL INDUSTRIES INC. accounted for 51.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Nurtec Odt.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 128 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| SUN PHARMACEUTICAL INDUSTRIES INC. | Unresolved — no canonical attribution shown | $23.57 | 51.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $21.81 | 48.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $45.38 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| YONSA Normalized: yonsa |
Drug | SUN PHARMACEUTICAL INDUSTRIES INC. | $23.57 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $21.81 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $21.81 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
128 | 38 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 289 | 91 |
| Losartan Potassium | Losartan Potassium | 241 | 74 |
| Levothyroxine Sodium | Levothyroxine Sodium | 216 | 60 |
| Metoprolol Succinate | Metoprolol Succinate | 204 | 63 |
| Furosemide | Furosemide | 178 | 56 |
| Prednisone | Prednisone | 167 | 111 |
| Omeprazole | Omeprazole | 166 | 53 |
| Amlodipine Besylate | Amlodipine Besylate | 157 | 47 |
| Lisinopril | Lisinopril | 156 | 48 |
| Eliquis | Apixaban | 128 | 38 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 117 | 43 |
| Hydrochlorothiazide | Hydrochlorothiazide | 108 | 31 |
| Gabapentin | Gabapentin | 106 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 105 | 33 |
| Pantoprazole Sodium | Pantoprazole Sodium | 104 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 103 | 29 |
| Metformin Hcl | Metformin Hcl | 101 | 31 |
| Sertraline Hcl | Sertraline Hcl | 97 | 35 |
| Tramadol Hcl | Tramadol Hcl | 97 | 31 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 79 | 24 |
| Pregabalin | Pregabalin | 65 | 17 |
| Azithromycin | Azithromycin | 64 | 54 |
| Carvedilol | Carvedilol | 63 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 63 | 20 |
| Potassium Chloride | Potassium Chloride | 63 | 20 |
| Trazodone Hcl | Trazodone Hcl | 63 | 22 |
| Meloxicam | Meloxicam | 60 | 20 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 56 | 53 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 51 | 41 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 50 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 49 | suppressed |
| Allopurinol | Allopurinol | 48 | 15 |
| Lorazepam | Lorazepam | 48 | suppressed |
| Jardiance | Empagliflozin | 47 | 14 |
| Simvastatin | Simvastatin | 47 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 45 | 14 |
| Famotidine | Famotidine | 44 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 43 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 43 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 41 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 41 | 13 |
| Atenolol | Atenolol | 39 | 11 |
| Diazepam | Diazepam | 39 | suppressed |
| Clonazepam | Clonazepam | 38 | 13 |
| Trulicity | Dulaglutide | 37 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 36 | 13 |
| Nitroglycerin | Nitroglycerin | 36 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 34 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 34 | suppressed |
| Baclofen | Baclofen | 33 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 33 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 33 | suppressed |
| Ozempic | Semaglutide | 33 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | 18 |
| Fluconazole | Fluconazole | 31 | 19 |
| Oxycodone Hcl | Oxycodone Hcl | 31 | 12 |
| Warfarin Sodium | Warfarin Sodium | 31 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 30 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 30 | 19 |
| Aripiprazole | Aripiprazole | 28 | suppressed |
| Bupropion Xl | Bupropion Hcl | 28 | suppressed |
| Methocarbamol | Methocarbamol | 28 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 28 | suppressed |
| Cephalexin | Cephalexin | 27 | 24 |
| Alendronate Sodium | Alendronate Sodium | 25 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 25 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 25 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 24 | 16 |
| Spironolactone | Spironolactone | 24 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 23 | suppressed |
| Levetiracetam | Levetiracetam | 23 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 23 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 22 | 16 |
| Sucralfate | Sucralfate | 22 | suppressed |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Alprazolam | Alprazolam | 20 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 20 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 20 | suppressed |
| Olanzapine | Olanzapine | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 17 |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 19 | suppressed |
| Temazepam | Temazepam | 19 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 18 | suppressed |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Tacrolimus | Tacrolimus | 18 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 17 | suppressed |
| Glimepiride | Glimepiride | 17 | suppressed |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 16 | suppressed |
| Finasteride | Finasteride | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Ezetimibe | Ezetimibe | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | 12 |
| Risperidone | Risperidone | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | 13 |
| Bumetanide | Bumetanide | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Cosentyx Sensoready (2 Pens) | Secukinumab | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Loperamide | Loperamide Hcl | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Amiloride Hcl | Amiloride Hcl | 11 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 11 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $45.38 · 2 records | SUN PHARMACEUTICAL INDUSTRIES INC. | NURTEC ODT, PAXLOVID, YONSA | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Nurtec Odt play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error